Induction Healthcare Dividends INHC

Dividends

No Dividend Data for INHC

Top Dividend Posts

Top Posts
Posted at 29/4/2024 09:46 by citys2874 Induction Healthcare Group PLC Full Year Trading Update London, UK - 29 April 2024: Induction Healthcare Group PLC ("Induction", the "Company", or the "Group"; AIM: INHC), a leading digital health platform driving transformation of healthcare systems, today announces the following trading update for the year ending 31 March 2024. Financial Highlights (unaudited) · Revenues of approximately £14.1m (FY23: £13.6m), broken down as follows: o Attend Anywhere: £8.5m o Zesty: £4.9m o Guidance: £0.7m · Adjusted EBITDA* expected to be in line with market expectation at approximately £0.3m (FY23: -£3.6m) · Gross margin improvement to 77.9% (FY23: 63.1%) · Net cash £3.7m (31 March 2023: £4.3m) * Adjusted EBITDA is Operating result from continuing operations before depreciation (£0.1m), amortisation (£4.3m) and net of non-cash/ non-operating items (£0.2m) Operational Highlights · New NHS patient portal contracts compensate for downward pressure on video pricing. · Completed effective cost containment and margin enhancement programme. · Achieved objective of self-sustaining growth and cash flow breakeven. · Signed a total of £3.4m (includes previously-announced contracts) in contracts with NHS England Trusts to: o Further integrate Zesty with Oracle Cerner and widely-used diagnostic booking systems (Cris and Soliton); o Enhance Form Builder module to support waitlist validation; and o Build new functionality, such as digitising maternity records. All platform and product enhancements underpin valuable upsell opportunities for FY25. · Launched Zesty in 4 new Trusts, including a new contract award in Q4 with George Elliot Hospital NHS Trust. Three additional Trusts are contracted to launch Zesty within the next 12 months. · Successfully built and launched the first phase of our integrated product which enables a patient to view and launch their Attend Anywhere consultation from within Zesty. Five customers have already purchased the integrated functionality. · NHS Wales agreed to a 9-month extension for £730,858 in order to prepare for a new procurement, which was expected under NHS procurement rules given the length of a new contract. Induction expects to release its audited results for the year ending 31 March 2024 on 1 July 2024. Read Full Thread Reply
Posted at 15/3/2021 22:56 by megasonic Built up a healthy holding in INHC these past few weeks. RNSs on a number of contract wins in the last few days and the resulting share price action suggest this was a wise investment.INHC looks a real solid MedTech business, seems to have plenty of buy in from medical professionals.Expecting a Trading Update next month that will hopefully reveal decent revenue growth and potential for future contract wins. Currently only 20% of float available to PIs so share price will see big moves on low volumes. share price might see a big bounce if TU is positive, but IMO the real reward will come from a long term hold. Read Full Thread Reply
Posted at 09/7/2020 12:51 by sphere25 Scubadiverr, In this instance, it's the well publicised Woodford debacle and Link Fund Solutions (holding 10.34% of the company's stock as per the RNS dated 09/06/2020) acting as administrator to place the funds. It has been a similar theme recently at the likes of PURP, TRX and DDDD. Identifying an overhang in general would be an interesting question. Beyond news highlighting distressed or forced fund sellers, you can look for persistent sellers via holding RNS and where stocks appear to be artificially suppressed from reaching a higher valuation. An example of this would be TSL where Simon Thompson has recently written an article on Investors Chronicle highlighting the increasing disparity between the valuation of the stock relative to the ever increasing value of the stake it has in AfterPay. TSL has substantially lagged the move higher in the company it owns a stake in and the holding RNS show that this appears to be because of Lombard using the opportunity of higher market demand to sell down a very significant stake. They have sold down their stake from 18.7% of the company in mid May to 4.51% as at the 30th June. There have been numerous overhang plays in the past, but note that there is no guarantee that the stock will rally strong too - it does depend on the fundamentals of the stock too, short term rises can be sold into or stale moves can occur. INHC is such an example as it's highly speculative and could find other sellers in the market wanting to sell at the overhang clearance levels, so it ultimately depends on the fundamentals. Clearly if this stock starts show more on the fundamental front, it changes the picture entirely. Hope this helps All imo DYOR Read Full Thread Reply